Is Gilteritinib an imported drug or a domestic drug market comparison?

Gilitinib is an oral FLT3 inhibitor, mainly used to treat relapsed or refractory FLT3 mutation-positive acute myeloid leukemia (AML). Currently in the Chinese market, the original drug gilitinib has been approved for marketing, but it is an imported drug and has not yet been included in the national medical insurance system. This means that it may be difficult for patients to purchase directly from domestic hospitals, especially when pharmacies or hospitals in some areas have limited inventory.

The foreign original research versions of gilitinib mainly include the European version and the Hong Kong version. Especially the Hong Kong version of giritinib, which is priced as high as about 100,000 yuan, is a high-priced imported drug. Due to its patent protection and import costs, the accessibility and economic burden of original drugs in the domestic market are high, and ordinary patients are under great pressure to use them for a long time. This also requires some patients to obtain drugs through overseas purchasing agents or other legal channels.

In contrast, giritinib also has generic drug options in foreign markets, such as the Laotian version. The price of generic drugs is only more than 1,000 to 2,000 yuan, which greatly reduces the economic burden. It is worth noting that such generic drugs are basically the same as the original drugs in terms of active ingredients and dosage, and can meet the treatment needs of most patients in terms of efficacy, providing a feasible option for patients with limited financial conditions or who are unable to obtain the original drugs in a timely manner.

Taken together, giritinib is mainly imported as the original drug in China, which is expensive and not included in medical insurance. There are certain obstacles for patients to purchase it. Foreign generic drugs are affordable and have basically the same ingredients, but they need to be purchased through formal and legal channels. Clinically, patients should choose a version of the drug that suits their own situation under the guidance of a doctor, taking into account efficacy, affordability, and accessibility to ensure continuity and safety of treatment.

Reference materials:https://www.drugs.com/